ubs maintains sell rating for docmorris with target price of 27 francs

DocMorris has been given a 'Sell' rating by UBS, with a price target of 27 francs, after the release of the company's third-quarter figures.

Sales were in line with expectations, but there may be a slightly negative reaction in the share price. DocMorris is falling behind its main German competitor in the prescription business, which could be a cause for concern among investors. The market is expected to respond to this competitive disadvantage.

Trending
Subcategory:
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings